SCHEMBL7016063

SCHEMBL7016063

Cc1c(-c2ccc([N+](=O)[O-])cc2)sc2c1c(=O)c(C(=O)c1ccccc1)cn2Cc1c(F)cccc1F

nearest known ligand 0.54

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
GNRHR P30968 20/20 0.54
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7493954 0.87 GNRHR (0.59) GNRHR
SCHEMBL7011418 0.86 GNRHR (0.73) GNRHRMEN1KMT2A
SCHEMBL8164246 0.85 GNRHR (0.43) GNRHR
SCHEMBL8160095 0.82 GNRHR (0.53) GNRHRMEN1KMT2A
SCHEMBL8165696 0.80 GNRHR (0.46) GNRHRMEN1KMT2A
SCHEMBL8160052 0.80 GNRHR (0.43) GNRHR
SCHEMBL7521084 0.79 GNRHR (0.61) GNRHRMEN1KMT2A
N-Benzylmethylamine SCHEMBL7750657 0.79 GNRHR (0.63) GNRHRMEN1KMT2A
SCHEMBL7504660 0.79 GNRHR (0.60) GNRHR
SCHEMBL7498273 0.79 GNRHR (0.67) GNRHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0756599-B1 BICYCLIC THIOPHENE DERIVATIVES AND USE AS GONADOTROPIN RELEASING HORMONE ANTAGONISTS TAKEDA CHEMICAL INDUSTRIES LTD (JP) 2003-11-26 EP disclosed
US-6329388-B2 GONADOTROPIN-RELEASING HORMONE ANTAGONIZING ACTIVITY; USEFUL FOR PREVENTING OR TREATING SEX HORMONE-DEPENDENT DISEASES, E.G., SEX HORMONE-DEPENDENT CANCERS (E.G., PROSTATIC CANCER, UTERINE CANCER, BREAST CANCER, PITUITARY TUMOR) TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2001-12-11 US disclosed
US-6297255-B1 GONADOTROPIN-RELEASING HORMONE ANTAGONIZING ACTIVITY; PREVENTING OR TREATING SEX HORMONE-DEPENDENT DISEASES TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2001-10-02 US disclosed
US-6262267-B1 HAS GONADOTROPIN-RELEASING HORMONE ANTAGONIZING ACTIVITY; USEFUL FOR PREVENTING OR TREATING SEX HORMONE-DEPENDENT DISEASES, E,G., SEX HORMONE-DEPENDENT CANCERS E.G., PROSTATIC CANCER, UTERINE CANCER, BREAST CANCER, PITUITARY TUMOR TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2001-07-17 US disclosed
US-20010001104-A1 Thienopyridine compounds, their production and use FURUYA SHUICHI (JP) 2001-05-10 US disclosed
EP-1090010-A1 THIENOPYRIDINE COMPOUNDS, THEIR PRODUCTION AND USE Takeda Chemical Industries, Ltd. (JP) 2001-04-11 EP disclosed
WO-2000000493-A1 THIENOPYRIDINE COMPOUNDS, THEIR PRODUCTION AND USE TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2000-01-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010001104-A1 Thienopyridine compounds, their production and use PRLHR, PGR, GNRHR GNRHR 3/4885MEN1 517/4885KMT2A 446/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.